Search results
Results from the WOW.Com Content Network
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
Novartis fought a seven-year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to ...
Swiss drug major Novartis AG (NYSE: NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent. The decision comes as the U.S. Court of ...
The Swiss competition commission (COMCO) has initiated an investigation against Novartis AG (NYSE: NVS) over the alleged unlawful patent use to reduce competitive pressure. COMCO conducted an ...
A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis drug Gilenya was invalid, potentially paving the way for introduction of ...
Chiron was the first to clone HCV in 1989 after six years of research [8] and had since filed over 100 HCV related patents in over 20 countries. [31] A settlement was reached where Roche Holding A.G. agreed to buy the global semi-exclusive nucleic acid test (NAT) patents for HCV and HIV from Chiron. [ 25 ]
Patent cliff refers to a dramatic dip in the revenue of a merchandise upon patent expiry. [32] It is a prominent phenomenon in the proprietary drug industry due to the vast gap of prices between the proprietary drug and the generic drug. [33] Since 2010, numerous pharmaceutical board busters have started to become off-patent. [34]
At Novartis, patent expiration for blockbuster drugs Diovan and Zometa shaved more than $2 billion from the top line in 2013. Sales of blood pressure drug Diovan sank 20% and revenue from Zometa ...